Catch up with the latest happenings at Terremoto.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the appointment of James Christensen, Ph.D., as Chief Executive Officer.
Terremoto Biosciences announced that it received Fast Track Designation granted for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN-alterations following endocrine therapy and CDK4/6 inhibitor therapy
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Sorry, no posts matched your criteria
Terremoto Biosciences, Inc. (“Terremoto”, “our”, “us”) collects, shares, and stores your personal information through cookies and similar technologies for purposes such as supporting our marketing efforts, personalizing your experience on our websites, and improving the performance of our websites.
By clicking the “Accept All” button below, you grant to us your consent to collect and process your personal information in accordance with our Privacy Notices.
If you choose to do so, you may personalize your specific preferences with regard to our use of cookies and similar technologies by clicking the “Preferences” button below and selecting which cookies you allow us to collect, or by clicking the “Reject All” button, you can reject all cookies. However, you will not be able to reject or de-select Essential Cookies which are necessary cookies that allow us to operate our websites.
View our Privacy Notices.
Terremoto’s websites may use the following categories of cookies. By default, all categories of cookies are turned ‘off’ except Essential cookies which are always turned ‘on’. You may select your cookie preferences for this website using the ‘on/off’ toggles for each category of cookies. Additional information about the various categories of cookies can be found in our Privacy Notices.
To exercise any other rights you have under applicable data privacy and data protection regulations, you may follow the process outlined in our Privacy Notices.
These trackers are used for activities that are strictly necessary to operate or deliver the service(s) you requested from us and, therefore, do not require you to consent.
CloudFlare provides web performance and security solutions, enhancing site speed and protecting against threats.
Service URL: developers.cloudflare.com (opens in a new window)
These cookies are needed for adding comments on this website.
These are cookies used to collect information about how visitors use our websites and to improve the websites by collecting information on how you interact with the websites.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com (opens in a new window)
You can find more information in our Privacy Policy and .
Terremoto Biosciences Appoints James Christensen, Ph.D., as Chief Executive Officer
/in 2026, Press Release/by ggindoyanTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the appointment of James Christensen, Ph.D., as Chief Executive Officer.
Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer
/in 2026, Press Release/by eallisonTerremoto Biosciences announced that it received Fast Track Designation granted for TER-2013 in HR+/HER2- breast cancer with AKT/PI3K/PTEN-alterations following endocrine therapy and CDK4/6 inhibitor therapy
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
/in 2026, Press Release/by David AndersonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $108 million Series C financing round.
Terremoto Biosciences Appoints James Christensen, Ph.D., as President, Head of Research & Development
/in 2025, Press Release/by Jane ShankTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of James Christensen, Ph.D., as President and Head of Research & Development.
Terremoto Biosciences Appoints Charles Baum, M.D., Ph.D., as Chief Executive Officer
/in 2024, Press Release/by Jane ShankTerremoto Biosciences, a biotechnology company developing first- and best-in-class targeted, therapeutics, today announced the appointment of Charles Baum, M.D., Ph.D., as Chief Executive Officer.
Terremoto Biosciences Closes $175 Million Series B Financing
/in 2023, Press Release/by David AndersonTerremoto Biosciences, a biotechnology company developing highly targeted, small molecule medicines, today announced the closing of a $175 million Series B financing round.
Terremoto Biosciences Launches With $75 Million Series A Financing and Mission to Discover and Develop Groundbreaking Covalent Medicines
/in 2022, Press Release/by eallisonTerremoto Biosciences, a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines, today announced it has raised $75 million in a Series A financing.